Our products help improve patient outcomes in our key focus areas, supported by clinical evidence and stringent Swiss quality standards.
We develop world-class treatments for Musculoskeletal Disorders, Ophthalmology and Neurology – blending Swiss precision with a family-driven commitment to care, quality and safety.
Our expertiseOur products help improve patient outcomes in our key focus areas, supported by clinical evidence and stringent Swiss quality standards.

Swissmedic-authorised and GMP-qualified production site in Vouvry, Switzerland, combining hyaluronic acid processing, ganglioside extraction, and an integrated R&D unit.
Explore our global production sites
Join us and be a part of developing healthcare worldwide, for future generations to come.
Papakonstantinou E, Roth M, Karakiulakis G. Hyaluronic acid: A key molecule in skin aging. Dermatoendocrinol. 2012;4(3):253-258.
Nguyen J, Werner L. (2017). Intraocular lenses for cataract surgery. In: Kolb H, Fernandez E, Nelson R, editors. Webvision: The Organization of the Retina and Visual System. Salt Lake City, UT: University of Utah Health Sciences Center.
Belda JI, Artola A, García-Manzanares MD, et al. Hyaluronic acid combined with mannitol to improve protection against free-radical endothelial damage: experimental model. J Cataract Refract Surg. 2005;31(6):1213-8.
Iaconisi GN, Gallo N, Caforio L, et al. Clinical and Biochemical Implications of Hyaluronic Acid in Musculoskeletal Rehabilitation: A Comprehensive Review. Journal of Personalized Medicine. 2023;13:1647.
Yanagisawa K. GM1 ganglioside and Alzheimer’s disease. Glycoconj J. 2015;32(3-4):105-12.
Schneider JS, Gollomp SM, Sendek S, et al. A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson’s disease patients. J Neurol Sci. 2013;324(1-2):140-8.
Alpaugh M, Galleguillos D, Forero J, et al. Disease-modifying effects of ganglioside GM1 in Huntington’s disease models. EMBO Mol Med. 2017;9(11):1537-1557.
Pavelka K, Bruyère O, Cooper C, et al. Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO. Drugs Aging. 2016;33(2):75-85.
Geisler FH, Dorsey FC, Coleman WP. Recovery of motor function after spinal-cord injury: a randomized, placebo-controlled trial with GM-1 ganglioside. N Engl J Med. 1991;324(26):1829-1838.